Osteoporosis is a progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.
Treatment with denosumab in patients with osteoporosis and diabetes yields a substantial increase in bone mineral density (BMD) and a reduction in the risk of vertebral, but not nonvertebral, fractures, a study has found.
Denosumab appears to have a neutral effect on the risk of composite and specific cardiovascular outcomes among patients with primary osteoporosis, whereas romosozumab may contribute to an increased risk of four-point major adverse cardiovascular event, according to the results of a meta-analysis.
The osteoporosis medications teriparatide, romosozumab, raloxifene and denosumab all confer significant benefits for reducing vertebral and hip fractures and inducing changes in bone mineral density at the femoral neck as compared with placebo, according to the results of a network meta-analysis.
Postmenopausal women who are younger, have higher levels of the bone turnover marker sCTX, and did not receive zoledronate prior to initiating denosumab treatment have an elevated risk of significant bone mineral density (BMD) loss 1 year after denosumab discontinuation, according to results of the ReoLaus* Bone Project presented at EULAR 2019.
Teriparatide appears to produce significant reductions in the incidence of fractures in the period beyond 6 months after treatment initiation, with the benefit consistently observed across important patient subgroups, according to data from four real-world studies.
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Denosumab yields increases in bone mineral density (BMD) in patients with glucocorticoid-induced osteoporosis (GIOP), and this benefit is not influenced by prior antiosteoporotic treatment, as shown in a study.
Patients with systemic sclerosis (SSc) or rheumatoid arthritis show lower trabecular bone score and bone mineral density compared with healthy individuals, according to a study. Moreover, SSc patients appear to have poorer bone quality with markedly altered microvasculature.
Men with systemic lupus erythematosus (SLE) are more likely to develop coronary artery calcifications (CAC) than age- and sex-matched controls, a recent study has shown. Such risk among patients with SLE is associated with older age, increasing chronic damage and cumulative dose of corticosteroids.